H. Plotkin

发表

H. Plotkin, 2004, BMJ : British Medical Journal.

Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance

H. Plotkin, E. Rold'an, J. Zanchetta, 1996, Calcified Tissue International.

Syndromes with congenital brittle bones

H. Plotkin, 2004, BMC pediatrics.

Bone Mass, Size, and Density in Children and Adolescents With Osteogenesis Imperfecta: Effect of Intravenous Pamidronate Therapy

F. Glorieux, H. Plotkin, F. Rauch, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions.

R. Engelbert, H. Plotkin, L. Dimeglio, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Bone mass in children: normative values for the 2-20-year-old population.

H. Plotkin, J. Zanchetta, J. Zanchetta, 1995, Bone.

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

F. Glorieux, H. Plotkin, N. Bishop, 1998, The New England journal of medicine.

Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.

F. Glorieux, H. Plotkin, F. Rauch, 2000, The Journal of clinical endocrinology and metabolism.

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.

F. Glorieux, H. Plotkin, F. Rauch, 2002, The Journal of clinical investigation.

Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.

F. Glorieux, H. Plotkin, F. Rauch, 2003, Pediatrics.

Special Report on the 2007 Pediatric Position Development Conference of the International Society for Clinical Densitometry

C. Gordon, H. Plotkin, B. Zemel, 2008, Southern medical journal.

Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.

F. Glorieux, H. Plotkin, F. Rauch, 2003, The Journal of clinical endocrinology and metabolism.

Bone Mineralization in Polyostotic Fibrous Dysplasia: Histomorphometric Analysis

F. Glorieux, H. Plotkin, F. Rauch, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.

F. Glorieux, H. Plotkin, F. Rauch, 2003, The Journal of clinical endocrinology and metabolism.

Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004

B. Wong, H. Plotkin, L. Bachrach, 2005, Neuromuscular Disorders.

Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.

H. Plotkin, A. F. Stewart, C. Gundberg, 1998, The Journal of clinical endocrinology and metabolism.

Growth and Growth Hormone Use in Osteogenesis Imperfecta

H. Plotkin, E. Germain-Lee, D. Digirolamo, 2014 .

Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease

F. Glorieux, H. Plotkin, P. Roughley, 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?

M. Patterson, H. Plotkin, Christina Lam, 2021, Molecular genetics and metabolism.

CHAPTER 18 – Osteogenesis Imperfecta

H. Plotkin, D. Rowe, D. Primorac, 2003 .

Comparable bioavailability of two esophago-gastric protective formulations containing pamidronate. A cross-over trial in healthy young adults.

H. Plotkin, J. Zanchetta, E. Roldán, 2002, Medicina.

Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.

A. Pestronk, J. Charrow, H. Plotkin, 2012, Molecular genetics and metabolism.

Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN

H. Plotkin, K. Kleopa, M. Beconi, 2017, Case reports in neurological medicine.

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

H. Plotkin, R. Komers, 2016, American journal of physiology. Regulatory, integrative and comparative physiology.

Conference on Endothelin Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

H. Plotkin, R. Komers, 2016 .

Hypophosphatasia - pathophysiology and treatment.

H. Plotkin, J. Millán, 2012, Actualizaciones en osteologia.

Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta.

F. Glorieux, H. Plotkin, F. Rauch, 2003, Pediatrics.

The Relationship Between Fractures and DXA Measures of BMD in the Distal Femur of Children and Adolescents With Cerebral Palsy or Muscular Dystrophy

B. Wong, H. Plotkin, B. Zemel, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bisphosphonates in children with bone diseases.

H. Plotkin, 2003, The New England journal of medicine.

Coalescing Expansile Skeletal Disease: Delineation Of An Extraordinary Osteopathy Involving The IFITM5 Mutation Of Osteogenesis Imperfecta Type V.

H. Plotkin, J. Aronson, S. Duan, 2020, Bone.

Surgical treatment of osteogenesis imperfecta: current concepts

H. Plotkin, P. Esposito, 2008, Current opinion in pediatrics.

Recombinant Enzyme Replacement Therapy in Hypophosphatasia.

H. Plotkin, F. Jakob, B. Mentrup, 2015, Sub-cellular biochemistry.

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

D. Sillence, O. Mäkitie, T. Hangartner, 2013, The Lancet.

Hypophosphatasia: Enzyme Replacement Therapy (Asfotase Alfa) Decreases TNSALP Substrate Accumulation And Improves Functional Outcomes In Affected Adolescents And Adults.

H. Plotkin, C. Greenberg, M. Whyte, 2012 .

Medical treatment of osteogenesis imperfecta

F. Glorieux, H. Plotkin, 2000 .

Bone Healing in Children With Osteogenesis Imperfecta Treated With Bisphosphonates

H. Plotkin, P. Álvarez, J. Pizones, 2005, Journal of pediatric orthopedics.

Two questions about osteogenesis imperfecta.

H. Plotkin, 2006, Journal of pediatric orthopedics.

Reliability of the Gross Motor Function Measure for Children with Osteogenesis Imperfecta

H. Plotkin, J. Hanley, J. Ruck-Gibis, 2001, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

H. Plotkin, J. Zanchetta, R. Capozza, 1998, Bone.

Hypophosphatasia: enzyme replacement therapy (ENB-0040) decreases TNSALP substrate accumulation and improves functional outcome in affected adolescents and adults

H. Plotkin, M. Whyte, P. Kishnani, 2012 .

Lumbar spine bone density in argentine children

H. Plotkin, J. Zanchetta, J. Zanchetta, 1996, Calcified Tissue International.

Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.

H. Plotkin, S. Coughlin, M. Bruzoni, 2006, Developmental medicine and child neurology.

Intravenous zoledronic acid (ZOL) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI)

I. Kaitila, F. Glorieux, H. Plotkin, 2008 .

Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry

S. Silverman, C. Gordon, H. Plotkin, 2008, Osteoporosis International.

Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.

A. Pestronk, J. Charrow, H. Plotkin, 2012, Molecular Genetics and Metabolism.

Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study

H. Plotkin, S. Coughlin, M. Bruzoni, 2006 .